GRAIL, Inc. operates as a commercial-stage healthcare company, which engages in the development of a technology for early detection of cancer. The company is headquartered in Menlo Park, California and currently employs 1,000 full-time employees. The company went IPO on 2024-06-12. The firm is focused on alleviating the global burden of cancer by using sequencing, population-scale clinical studies, and machine learning, software, and automation to detect and identify multiple deadly cancer types in earlier stages. Its targeted methylation-based platform can support the continuum of care for screening and precision oncology, including multi-cancer early detection in symptomatic patients, risk stratification, minimal residual disease detection, biomarker subtyping, treatment and recurrence monitoring. Its multi-cancer early detection test, the Galleri test, is a commercially available screening test for early detection of multiple types of cancer. The Galleri test can be used to screen for cancer before a person becomes symptomatic, when cancer may be more easily treated and potentially curable. The Galleri test can indicate the origin of the cancer.
Follow-Up Questions
¿Qué tal es el rendimiento del precio de la acción GRAL?
El precio actual de GRAL es de $80.02, ha decreased un 0.82% en el último día de negociación.
¿Cuáles son los temas de negocio principales o las industrias de Grail Inc?
Grail Inc pertenece a la industria Biotechnology y el sector es Health Care
¿Cuál es la capitalización bursátil de Grail Inc?
La capitalización bursátil actual de Grail Inc es $2.8B
¿Es Grail Inc una compra, una venta o una posición de mantener?
Según los analistas de Wall Street, 4 analistas han realizado calificaciones de análisis para Grail Inc, incluyendo 2 fuerte compra, 4 compra, 4 mantener, 0 venta, y 2 fuerte venta
